Core Viewpoint - A class action lawsuit has been filed against Quantum Corporation for violations of the Securities Exchange Act due to false and misleading statements regarding revenue recognition [1][2]. Group 1: Lawsuit Details - The class period for the lawsuit is from November 15, 2024, to August 18, 2025, with a deadline for lead plaintiff appointments set for November 3, 2025 [2]. - Quantum Corporation was required to restate prior financial statements because of improper revenue recognition, leading to claims that its public statements were materially misleading [2]. Group 2: Shareholder Participation - Shareholders who purchased shares during the specified class period are encouraged to contact the law firm for potential lead plaintiff appointments, although this is not necessary to participate in any recovery [2][3]. - Once registered, shareholders will be enrolled in a portfolio monitoring system to receive updates on the case's progress at no cost [3]. Group 3: Law Firm Background - DJS Law Group specializes in securities class actions and corporate governance litigation, representing large hedge funds and alternative asset managers [4].

Core Viewpoint - A class action lawsuit has been filed against Savara Inc. for alleged violations of securities laws, specifically related to misleading statements regarding its Biologics License Application (BLA) for MOLBREEVI [1][2]. Group 1: Lawsuit Details - The class period for the lawsuit is from March 7, 2024, to May 23, 2025, with a deadline for lead plaintiff appointments set for November 10, 2025 [2]. - The complaint alleges that Savara made false and misleading statements to the market, particularly regarding the adequacy of information provided in its BLA submitted to the FDA [2]. - It is claimed that the FDA was unlikely to approve Savara's BLA due to deficiencies in the information provided, which rendered the company's public statements materially misleading throughout the class period [2]. Group 2: Shareholder Participation - Shareholders who purchased shares during the specified class period are encouraged to contact the law firm for potential lead plaintiff appointments, although this is not a requirement for recovery [2][3]. - Once registered, shareholders will be enrolled in a portfolio monitoring system to receive updates on the case's status, with no cost or obligation to participate [3]. Group 3: Law Firm Background - DJS Law Group specializes in securities class actions and corporate governance litigation, focusing on enhancing investor returns through advocacy [4]. - The firm represents some of the largest hedge funds and alternative asset managers, emphasizing the value of litigation claims as significant assets [4].

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Fly-E Group, Inc. regarding a class action lawsuit due to allegations of misleading statements about the safety of its lithium batteries, which negatively impacted the company's E-vehicle sales and revenue projections [1]. Summary by Relevant Sections Allegations and Impact - The complaint alleges that Fly-E Group provided overly positive statements while concealing material adverse facts about the safety of its lithium batteries, leading to a significant decline in E-vehicle sales revenue [1]. - On August 14, 2025, Fly-E reported a 32% decrease in net revenues, primarily due to a drop in total units sold, which was attributed to recent lithium-battery accidents involving E-Bikes and E-Scooters [1]. - Following this revelation, Fly-E's stock price plummeted from $7.76 per share to $1.00 per share on August 15, 2025, marking an approximate decline of 87% in just one day [1]. Class Action Details - Shareholders who purchased shares during the class period from July 15, 2025, to August 14, 2025, are encouraged to register for the class action, with a deadline for lead plaintiff appointment set for November 10, 2025 [2]. - Registered shareholders will receive updates through a portfolio monitoring software throughout the lifecycle of the case, with no cost or obligation to participate [2]. Law Firm's Commitment - The Gross Law Firm is recognized for protecting investors' rights against deceit and fraud, emphasizing the importance of responsible business practices and corporate citizenship [3].

Core Viewpoint - Savara Inc. (NASDAQ: SVRA) is facing a class action lawsuit due to allegations of issuing materially false and misleading statements regarding its drug MOLBREEVI, which is intended for the treatment of pulmonary alveolar proteinosis [3][4]. Group 1: Allegations and Class Period - The class period for the lawsuit is from March 4, 2024, to May 23, 2025 [3]. - Allegations include that Savara failed to disclose critical information about MOLBREEVI's chemistry, manufacturing, and controls, leading to doubts about FDA approval [3]. - The complaint suggests that the delay in regulatory approval would likely necessitate Savara to raise additional capital [3]. Group 2: Shareholder Actions - Shareholders who purchased SVRA shares during the class period are encouraged to register for the class action, with a deadline of November 7, 2025, to seek lead plaintiff status [4]. - Once registered, shareholders will receive updates through a portfolio monitoring software regarding the case's progress [4]. Group 3: Law Firm's Role - The Gross Law Firm is representing the shareholders and is recognized for its commitment to protecting investors' rights against deceit and fraud [5]. - The firm aims to ensure that companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements [5].

Core Viewpoint - The Gross Law Firm has announced a class action lawsuit on behalf of shareholders of Sable Offshore Corp. (NYSE: SOC) who purchased shares during a specified class period, alleging that the company made materially false and misleading statements regarding its oil production activities [1][2]. Group 1: Allegations - The complaint claims that Sable Offshore Corp. falsely represented that it had restarted oil production off the coast of California when it had not, leading to materially misleading statements about the company's business and operations [2]. - The lawsuit asserts that when the true information became public, investors suffered damages due to the inflated stock price resulting from these misleading statements [2]. Group 2: Class Action Details - The class period for the lawsuit is defined as May 19, 2025, to June 3, 2025, inclusive, including shares purchased during the company's secondary public offering on May 21, 2025 [1]. - Shareholders are encouraged to register for the class action by September 26, 2025, to potentially be appointed as lead plaintiffs, although this is not required to participate in any recovery [3]. Group 3: Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting the rights of investors who have suffered losses due to deceit and illegal business practices [4]. - The firm aims to ensure that companies adhere to responsible business practices and seeks recovery for investors affected by false or misleading statements [4].

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Novo Nordisk A/S regarding a class action lawsuit due to allegations of misleading statements about the company's growth potential and subsequent stock price decline [1][3]. Summary by Relevant Sections Allegations - The complaint alleges that Novo Nordisk provided overly positive statements while concealing material adverse facts about its growth potential, particularly regarding the compounded GLP-1 market and the likelihood of patients switching to its branded alternatives [3]. - The company overstated its capability to penetrate the GLP-1 market, which led to inflated expectations among investors [3]. Stock Performance - Following the announcement on July 29, 2025, that Novo would lower its sales and profit outlook due to "lowered growth expectations for the second half of 2025," the stock price fell dramatically from $69.00 per share to $53.94 per share, a decline of approximately 21.83% in one day [3]. Class Action Details - The class period for the lawsuit is from May 7, 2025, to July 28, 2025, and shareholders are encouraged to register for participation by September 30, 2025 [4]. - There is no cost or obligation for shareholders to participate in the case, and they will receive updates through a portfolio monitoring software [4]. Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights and ensuring companies adhere to responsible business practices [5].

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Lineage, Inc. regarding a class action lawsuit related to the company's initial public offering (IPO) on July 26, 2024, alleging that the company made materially false and misleading statements about its financial health and business operations [1][3][4]. Summary by Relevant Sections Class Action Details - The lawsuit is on behalf of all purchasers of Lineage common stock during the specified class period linked to the IPO [3]. - Shareholders are encouraged to register for participation in the class action, with a deadline set for September 30, 2025 [5]. Allegations Against Lineage, Inc. - The complaint alleges that Lineage experienced a decline in customer demand due to increased cold-storage supply and a destocking of excessive inventory from the COVID-19 pandemic [4]. - It is claimed that the company implemented unsustainable price increases prior to the IPO, which could not be maintained amid weakening demand [4]. - Lineage reportedly failed to counteract adverse trends through operational efficiencies or competitive advantages, leading to stagnant or declining revenue, occupancy rates, and rent prices [4]. - The allegations suggest that the company's financial results and business prospects were materially impaired as a result of these issues [4]. Next Steps for Shareholders - Shareholders who register will be enrolled in a portfolio monitoring system to receive updates on the case [5]. - There is no cost or obligation for shareholders to participate in the class action [5]. Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm focused on protecting investors' rights against deceit and fraud [6].

Core Viewpoint - Capricor Therapeutics, Inc. is facing a class action lawsuit due to allegations of misleading statements regarding its lead cell therapy candidate, deramiocel, for treating cardiomyopathy associated with Duchenne muscular dystrophy (DMD) [2][4]. Group 1: Allegations and Impact - The lawsuit claims that Capricor provided investors with overly positive information about its ability to obtain a Biologics License Application (BLA) from the FDA while concealing adverse facts about the safety and efficacy data from its Phase 2 HOPE-2 trial [2]. - Following the announcement of a Complete Response Letter (CRL) from the FDA on July 11, 2025, which denied the BLA due to insufficient evidence of effectiveness and the need for additional clinical data, Capricor's stock price fell from $11.40 to $7.64 per share [2]. Group 2: Class Action Details - The class period for the lawsuit is defined as October 9, 2024, to July 10, 2025, and shareholders are encouraged to register for potential lead plaintiff appointment [2][3]. - The deadline for shareholders to seek lead plaintiff status is September 15, 2025, and there is no cost or obligation to participate in the case [3]. Group 3: Legal Representation - The Gross Law Firm, a nationally recognized class action law firm, is representing the shareholders and aims to protect investors' rights against deceit and fraud [4]. - The firm emphasizes its commitment to ensuring responsible business practices and seeks recovery for investors who suffered losses due to misleading statements [4].

Core Viewpoint - Cybin Inc. is under investigation by the Schall Law Firm for potential violations of securities laws, particularly regarding misleading statements and failure to disclose important information to investors [2]. Company Summary - The investigation is focused on whether Cybin issued false or misleading statements or failed to disclose relevant information to investors [2]. - Following the announcement of CEO Doug Drysdale's resignation on September 2, 2025, Cybin's shares dropped by over 16.5% on the same day [2]. Legal Context - The Schall Law Firm is representing investors globally and specializes in securities class action lawsuits and shareholder rights litigation [3].

Sep 5, 2025 12:20 PM Eastern Daylight Time Fiserv, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - FI Share LOS ANGELES--(BUSINESS WIRE)--The DJS Law Group reminds investors of a class action lawsuit against Fiserv, Inc. ("Fiserv†or "the Company†) (NYSE: FI) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Shareholders who purchased shares of FI durin ...